LevEllis, Inc., a pioneering biotechnology-driven skincare company founded by renowned surgeon and molecular biologist Dr. Laura Ellis, proudly announces the official launch of PROVOQUE, a revolutionary regenerative serum setting new standards in medical-grade skincare.
Powered by proprietary secretome technology derived from human skin progenitor cells, PROVOQUE delivers a complete skin-specific secretome, a potent, naturally balanced matrix of peptides, growth factors, cytokines, microRNA, exosomes, and regenerative biomolecules. Unlike products that rely on isolated components, PROVOQUE mimics the body’s native regenerative environment for superior restoration, repair, and renewal.
“We are thrilled to introduce a next-generation advancement in regenerative aesthetics—one that offers new potential for both skin and hair revitalization” said Dr. Ellis. “As regenerative medicine reshapes the future of aesthetics, PROVOQUE stands at the intersection of scientific evidence, innovation, and elegance.”
Clinically validated and physician-dispensed, PROVOQUE is formulated without fragrances, oils, detergents, or organic solvents, preserving the bioactivity of its advanced cellular components while minimizing inflammation and risk of irritation. It features Fetuin-A, a glycoprotein critical to cellular communication and regeneration, and delivers visible improvements to skin health in as little as 14 days, according to a peer-reviewed study published in the Journal of Drugs in Dermatology.
“What truly distinguishes PROVOQUE, is that it is built upon skin-specific cellular science. These young, bioengineered skin progenitor cells produce the complete skin secretome — a robust, biologically active blend of naturally occurring growth factors, exosomes, and the glycoprotein Fetuin-A,” said Hans Keirstead, PhD, inventor of the PROVOQUE technology and internationally recognized stem cell expert. “A Dermatology assessed, peer reviewed study published in Journal of Drugs in Dermatology shows it reveals healthier, smoother-looking skin from the inside out in as early as 14 days.”
LevEllis, Inc. is supported by a distinguished scientific advisory board, including experts Dr. Julie Woodward, Dr. Jordan R. Plews, and Dr. Gabriel Nistor, leaders in oculofacial surgery, dermatology, and regenerative medicine, ensuring LevEllis remains a scientific force in the future of skincare.
